Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ · Healthcare
$17.45-1.69%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.45B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,081,047
- 52-week high
- —
- 52-week low
- —
- Open
- $18.00
- Day high
- $18.53
- Day low
- $17.44
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $0 | -$144.74M | -$1.53 |
| 2024 | $87.37M | -$301.74M | -$4.43 |
| 2023 | $380.79M | $49.27M | $0.70 |
| 2022 | $22.23M | -$198.38M | -$3.39 |
| 2021 | $285K | -$87.93M | -$13.35 |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
- CEO
- Joshua Cohen
- Employees
- 136
- Country
- US
- IPO date
- Jan 7, 2022
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Amylyx Pharmaceuticals, Inc.'s stock price today?
- AMLX is trading at $17.45 as of Jul 20, 2026.
- What is Amylyx Pharmaceuticals, Inc.'s market cap?
- Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $1.45B.
- Does Amylyx Pharmaceuticals, Inc. pay a dividend?
- Amylyx Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Amylyx Pharmaceuticals, Inc. in?
- Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector.